The US Food and Drug Administration (FDA) has approved Axsome Therapeutics’ Auvelity (dextromethorphan HBr -bupropion HCl) to treat adult patients with major depressive disorder (MDD).
22 Aug 2022
05 Aug 2022
Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).
15 Jul 2022
SK Biopharmaceuticals has signed a licensing agreement with Eurofarma, a Brazilian pharmaceutical company, to develop and commercialise cenobamate in Latin America for epilepsy treatment.
19 May 2022
SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.
05 May 2022
Apnimed has raised $62.5m funding in a Series C round led by new investor Sectoral Asset Management to advance new pharmaceutical treatments development for obstructive sleep apnea (OSA) and related sleep disorders.
02 May 2022
The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.
28 Apr 2022
Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).
23 Feb 2022
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for its therapy cariprazine (VRAYLAR) to treat major depressive disorder (MDD).
18 Jan 2022
Neurimmune and Ono Pharmaceutical have announced the expansion of a drug discovery partnership agreement to develop antibody drugs for neurodegenerative diseases.
11 Jan 2022
Pfizer and Beam Therapeutics have entered into an exclusive four-year research collaboration focused on in vivo base editing programmes for three targets for rare genetic diseases of liver, central nervous system, liver and muscle.